Metastatic or locally advanced mediastinal neuroendocrine tumours: outcome with 177Lu-DOTATATE-based peptide receptor radionuclide therapy and assessment of prognostic factors

Simple item page
dc.contributor.authorAdnan, A.
dc.contributor.authorKudachi, S.
dc.contributor.authorRamesh, S.
dc.contributor.authorPrabhash, K.
dc.contributor.authorBasu, Sandip
dc.date.accessioned2020-11-25T06:21:47Z
dc.date.available2020-11-25T06:21:47Z
dc.date.issued2019
dc.description.divisionRMCen
dc.format.extent5598 bytes
dc.format.mimetypetext/html
dc.identifier.sourceNuclear Medicine Communications, 2019. Vol. 40 (9)en
dc.identifier.urihttp://hdl.handle.net/123456789/21429
dc.language.isoenen
dc.subject177Lu-DOTATATEen
dc.subjectmediastinal neuroendocrine tumouren
dc.subjectneuroendocrine tumouren
dc.subjectpeptide receptor radionuclide therapyen
dc.subjectthymic neuroendocrine tumouren
dc.titleMetastatic or locally advanced mediastinal neuroendocrine tumours: outcome with 177Lu-DOTATATE-based peptide receptor radionuclide therapy and assessment of prognostic factorsen
dc.typeArticleen

Click here to download

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
1127.htm
Size:
5.47 KB
Format:
Hypertext Markup Language
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.81 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

2019